Autopsy report · NCT02318537

Cannabidiol Oral Solution as an Adjunctive Therapy for Treatment of Participants With Inadequately Controlled Lennox-Gastaut Syndrome

“Sponsor elected not to continue with study.”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Phase 3

Sponsor

INSYS Therapeutics Inc

Sponsor type

Industry

Conditions

Lennox-Gastaut Syndrome

Interventions

Cannabidiol Oral Solution; Placebo Solution

Participants

0

Trials that died the same way

• Manual Therapy/Exercises vs. Physiotherapy/Back School vs. Waiting List in Patients With Chronic Low Back Pain
  “Sponsor did not want to continue the study.” (82% match in meaning)
• Molecular Characterization of CTCs and ctDNA in Blood and Plasma Samples From Patients With Metastatic and/or Hormone-Resistant Prostate Cancer
  “Sponsor decided not to pursue study” (80% match in meaning)
• Comparative Mixture of Non-racemic and Racemic Enantiomers of Bupivacaine in Cesarean
  “The Sponsor has no interest in continuing the study.” (76% match in meaning)
• SUBA-Itraconazole Therapy for Coccidioidomycosis Refractory or Intolerant to Fluconazole
  “Sponsor is not proceeding with study due to budget cuts as a result of COVID-19.” (72% match in meaning)
• Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta
  “Sponsor decision to prematurely stop the study, not linked to any safety concern.” (72% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.